Equities analysts expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to announce ($1.28) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($1.21) and the highest is ($1.20). Atara Biotherapeutics posted earnings per share of ($1.15) during the same quarter last year, which suggests a negative year over year growth rate of 11.3%. The company is scheduled to issue its next earnings results on Tuesday, February 26th.
On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.58) per share for the current fiscal year, with EPS estimates ranging from ($4.59) to ($4.58). For the next year, analysts anticipate that the firm will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by ($0.16).
In related news, insider Joe Newell sold 1,500 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $39.45, for a total transaction of $59,175.00. Following the completion of the transaction, the insider now directly owns 33,358 shares in the company, valued at $1,315,973.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Christopher Haqq sold 775 shares of the business’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $37.54, for a total value of $29,093.50. Following the transaction, the executive vice president now owns 331,355 shares of the company’s stock, valued at $12,439,066.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,249 shares of company stock valued at $3,592,222. 10.60% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of ATRA. BlackRock Inc. grew its position in Atara Biotherapeutics by 18.3% during the second quarter. BlackRock Inc. now owns 3,364,604 shares of the biotechnology company’s stock worth $123,650,000 after buying an additional 520,163 shares in the last quarter. JPMorgan Chase & Co. grew its position in Atara Biotherapeutics by 35.6% during the third quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock worth $49,741,000 after buying an additional 315,921 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Atara Biotherapeutics by 74.8% during the third quarter. Assenagon Asset Management S.A. now owns 415,520 shares of the biotechnology company’s stock worth $17,182,000 after buying an additional 177,852 shares in the last quarter. Eagle Asset Management Inc. grew its position in Atara Biotherapeutics by 11.2% during the third quarter. Eagle Asset Management Inc. now owns 1,624,958 shares of the biotechnology company’s stock worth $67,192,000 after buying an additional 164,219 shares in the last quarter. Finally, Northern Trust Corp grew its position in Atara Biotherapeutics by 27.1% during the second quarter. Northern Trust Corp now owns 497,371 shares of the biotechnology company’s stock worth $18,278,000 after buying an additional 105,935 shares in the last quarter.
Shares of NASDAQ ATRA opened at $37.83 on Tuesday. The firm has a market capitalization of $1.67 billion, a PE ratio of -9.46 and a beta of 2.59. Atara Biotherapeutics has a fifty-two week low of $12.65 and a fifty-two week high of $54.45.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
See Also: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.